Filing Details
- Accession Number:
- 0001415889-24-011251
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-04-19 18:00:15
- Reporting Period:
- 2024-04-17
- Accepted Time:
- 2024-04-19 18:00:15
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1798749 | Aerovate Therapeutics Inc. | AVTE | Pharmaceutical Preparations (2834) | 831377888 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1868997 | Hunter Gillies | C/O Aerovate Therapeutics, Inc. 930 Winter Street, Suite M-500 Waltham MA 02451 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-04-17 | 4,000 | $1.74 | 7,251 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-04-17 | 3,689 | $22.30 | 3,562 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-04-17 | 311 | $23.33 | 3,251 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-04-17 | 503 | $0.00 | 503 | $1.74 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-04-17 | 3,497 | $0.00 | 3,497 | $1.74 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 2,511 | 2030-09-03 | No | 4 | M | Direct | |
| 539 | 2030-09-03 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.08 to $22.80, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.12 to $23.97, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
- A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Billionaire Hedge Funds
